razaxaban has been researched along with ticlopidine in 1 studies
| Studies (razaxaban) | Trials (razaxaban) | Recent Studies (post-2010) (razaxaban) | Studies (ticlopidine) | Trials (ticlopidine) | Recent Studies (post-2010) (ticlopidine) |
|---|---|---|---|---|---|
| 20 | 0 | 2 | 10,289 | 1,893 | 4,671 |
| Protein | Taxonomy | razaxaban (IC50) | ticlopidine (IC50) |
|---|---|---|---|
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.382 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 6.2928 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.304 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 1.175 | |
| Cytochrome P450 2B6 | Homo sapiens (human) | 0.405 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.6678 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.426 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crain, EJ; Knabb, RM; Lam, PY; Quan, ML; Watson, CA; Wexler, RR; Wong, PC | 1 |
1 other study(ies) available for razaxaban and ticlopidine
| Article | Year |
|---|---|
Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
Topics: Animals; Aspirin; Blood Coagulation; Clopidogrel; Disease Models, Animal; Drug Therapy, Combination; Factor Xa; Fibrinolytic Agents; Hemorrhage; Hemostasis; Isoxazoles; Male; Platelet Aggregation; Pyrazoles; Rabbits; Thrombosis; Ticlopidine | 2007 |